These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 23348763)

  • 1. Differentiation of primary central nervous system lymphomas and glioblastomas: comparisons of diagnostic performance of dynamic susceptibility contrast-enhanced perfusion MR imaging without and with contrast-leakage correction.
    Toh CH; Wei KC; Chang CN; Ng SH; Wong HF
    AJNR Am J Neuroradiol; 2013; 34(6):1145-9. PubMed ID: 23348763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiation of brain abscesses from glioblastomas and metastatic brain tumors: comparisons of diagnostic performance of dynamic susceptibility contrast-enhanced perfusion MR imaging before and after mathematic contrast leakage correction.
    Toh CH; Wei KC; Chang CN; Ng SH; Wong HF; Lin CP
    PLoS One; 2014; 9(10):e109172. PubMed ID: 25330386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation between primary central nervous system lymphoma and glioblastoma: a comparative study of parameters derived from dynamic susceptibility contrast-enhanced perfusion-weighted MRI.
    Nakajima S; Okada T; Yamamoto A; Kanagaki M; Fushimi Y; Okada T; Arakawa Y; Takagi Y; Miyamoto S; Togashi K
    Clin Radiol; 2015 Dec; 70(12):1393-9. PubMed ID: 26382744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Value of Vascular Permeability Estimates Using Dynamic Susceptibility Contrast MRI: Improved Diagnostic Performance in Distinguishing Hypervascular Primary CNS Lymphoma from Glioblastoma.
    Lee B; Park JE; Bjørnerud A; Kim JH; Lee JY; Kim HS
    AJNR Am J Neuroradiol; 2018 Aug; 39(8):1415-1422. PubMed ID: 30026384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Permeability measurement using dynamic susceptibility contrast magnetic resonance imaging enhances differential diagnosis of primary central nervous system lymphoma from glioblastoma.
    Lee JY; Bjørnerud A; Park JE; Lee BE; Kim JH; Kim HS
    Eur Radiol; 2019 Oct; 29(10):5539-5548. PubMed ID: 30877463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of Percentage Signal Recovery and Baseline Signal in DSC-MRI Optimized for Relative CBV Measurement for Differentiating Glioblastoma, Lymphoma, Metastasis, and Meningioma.
    Lee MD; Baird GL; Bell LC; Quarles CC; Boxerman JL
    AJNR Am J Neuroradiol; 2019 Sep; 40(9):1445-1450. PubMed ID: 31371360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of dynamic contrast-enhanced magnetic resonance imaging for differentiating glioblastoma, primary central nervous system lymphoma and brain metastatic tumor.
    Lu S; Gao Q; Yu J; Li Y; Cao P; Shi H; Hong X
    Eur J Radiol; 2016 Oct; 85(10):1722-1727. PubMed ID: 27666608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of pseudo-continuous arterial spin labelling and dynamic susceptibility contrast MRI with and without contrast agent leakage correction in paediatric brain tumours.
    Novak J; Withey SB; Lateef S; MacPherson L; Pinkey B; Peet AC
    Br J Radiol; 2019 Feb; 92(1094):20170872. PubMed ID: 30358415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved performance of non-preloaded and high flip-angle dynamic susceptibility contrast perfusion-weighted imaging sequences in the presurgical differentiation of brain lymphoma and glioblastoma.
    Wang F; Zhou X; Chen R; Kang J; Yang X; Lin J; Liu F; Cao D; Xing Z
    Eur Radiol; 2023 Dec; 33(12):8800-8808. PubMed ID: 37439934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective comparative diagnostic accuracy evaluation of dynamic contrast-enhanced (DCE) vs. dynamic susceptibility contrast (DSC) MR perfusion in differentiating tumor recurrence from radiation necrosis in treated high-grade gliomas.
    Zakhari N; Taccone MS; Torres CH; Chakraborty S; Sinclair J; Woulfe J; Jansen GH; Cron GO; Thornhill RE; McInnes MDF; Nguyen TB
    J Magn Reson Imaging; 2019 Aug; 50(2):573-582. PubMed ID: 30614146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging.
    Liao W; Liu Y; Wang X; Jiang X; Tang B; Fang J; Chen C; Hu Z
    Acta Radiol; 2009 Mar; 50(2):217-25. PubMed ID: 19096950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiparametric analysis from dynamic susceptibility contrast-enhanced perfusion MRI to evaluate malignant brain tumors.
    Abreu VS; Tarrio J; Silva J; Almeida F; Pinto C; Freitas D; Filipe JP
    J Neuroimaging; 2024; 34(2):257-266. PubMed ID: 38173078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary central nervous system lymphoma and glioblastoma: differentiation using dynamic susceptibility-contrast perfusion-weighted imaging, diffusion-weighted imaging, and (18)F-fluorodeoxyglucose positron emission tomography.
    Nakajima S; Okada T; Yamamoto A; Kanagaki M; Fushimi Y; Okada T; Arakawa Y; Takagi Y; Miyamoto S; Togashi K
    Clin Imaging; 2015; 39(3):390-5. PubMed ID: 25547624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discrimination between Glioblastoma and Solitary Brain Metastasis: Comparison of Inflow-Based Vascular-Space-Occupancy and Dynamic Susceptibility Contrast MR Imaging.
    Li X; Wang D; Liao S; Guo L; Xiao X; Liu X; Xu Y; Hua J; Pillai JJ; Wu Y
    AJNR Am J Neuroradiol; 2020 Apr; 41(4):583-590. PubMed ID: 32139428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved Leakage Correction for Single-Echo Dynamic Susceptibility Contrast Perfusion MRI Estimates of Relative Cerebral Blood Volume in High-Grade Gliomas by Accounting for Bidirectional Contrast Agent Exchange.
    Leu K; Boxerman JL; Cloughesy TF; Lai A; Nghiemphu PL; Liau LM; Pope WB; Ellingson BM
    AJNR Am J Neuroradiol; 2016 Aug; 37(8):1440-6. PubMed ID: 27079371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal, leakage corrected and uncorrected rCBV during the first-line treatment of glioblastoma: a prospective study.
    Steidl E; Müller M; Müller A; Herrlinger U; Hattingen E
    J Neurooncol; 2019 Sep; 144(2):409-417. PubMed ID: 31321614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary brain lymphoma and glioblastoma: evaluation of DCE T1 and DSC T2 MRI perfusion findings.
    Soydan H; Sözmen Cılız D; Cesur T; Tezgör Aksakal E
    Acta Radiol; 2024 Jul; 65(7):800-807. PubMed ID: 38798137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary central nervous system lymphoma and atypical glioblastoma: differentiation using the initial area under the curve derived from dynamic contrast-enhanced MR and the apparent diffusion coefficient.
    Choi YS; Lee HJ; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
    Eur Radiol; 2017 Apr; 27(4):1344-1351. PubMed ID: 27436023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of microvascular permeability with dynamic contrast-enhanced MRI for the differentiation of primary CNS lymphoma and glioblastoma: radiologic-pathologic correlation.
    Kickingereder P; Sahm F; Wiestler B; Roethke M; Heiland S; Schlemmer HP; Wick W; von Deimling A; Bendszus M; Radbruch A
    AJNR Am J Neuroradiol; 2014 Aug; 35(8):1503-8. PubMed ID: 24722313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiating Between Primary Central Nervous System Lymphomas and Glioblastomas: Combined Use of Perfusion-Weighted and Diffusion-Weighted Magnetic Resonance Imaging.
    Makino K; Hirai T; Nakamura H; Kuroda JI; Shinojima N; Uetani H; Kitajima M; Yano S
    World Neurosurg; 2018 Apr; 112():e1-e6. PubMed ID: 29104150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.